Newly reported from EULAR 2024 - Brian LaMoreaux, MD: Defining and Achieving Remission in Gout with Pegloticase
The MIROR program was originally developed to test the idea that concomitant methotrexate and pegloticase therapy could prevent the development of anti-drug antibodies, which often limit the treatment’s effectiveness. The results were very successful. Patients with gout receiving methotrexate had a 71% response rate at 6 months, compared with 39% for those receiving a placebo. These results were also sustainable, with response rates at 12 months of approximately 60% for the methotrexate group and 30% for the placebo group.
In an interview with HCPLive, Brian LaMoreaux, MD, executive medical director at Amgen, discussed a post hoc analysis of the trial which focused on gout remission among these patients. Data were presented at the 2024 European Congress of Rheumatology (EULAR).
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
